Incidentalomas, How Radiologists Decide What Is Worth Chasing

The short answer#

An incidentaloma is a finding a scan turns up by accident, a spot on the film that has nothing to do with the reason your study was ordered. Radiologists do not pursue all of them, and careful radiology holds that they should not. Every incidental finding sits between two mistakes: dismissing a rare early cancer, or launching a cascade of tests for something that was never going to cause harm. The whole discipline of incidental-findings management exists to steer between those two errors, using the probability that a finding matters rather than the reflex to investigate anything the scanner shows.

Key points#

• An incidentaloma is an unexpected finding on imaging done for an unrelated reason.
• Whether to work it up depends on how likely it is to change care, weighed against the harm of chasing it.
• Size thresholds, imaging features, and patient history shift that probability up or down.
• Professional bodies publish organ-by-organ algorithms so the decision rests on evidence, not instinct.
• Comparison with a prior scan resolves many findings without any new test.

Why a single rule cannot work#

Modern cross-sectional imaging is very good at showing detail, including detail no one asked to see. As scanners improved, incidental findings stopped being occasional curiosities and became a routine management problem. A 2018 umbrella review in The BMJ by O'Sullivan and colleagues, which pooled twenty systematic reviews, put numbers on it: the frequency of incidental findings ranges from under 5 percent in some settings, such as whole-body PET, to more than a third in others, such as chest CT and cardiac MRI.

The same review showed why a blanket policy is doomed. The chance that an incidentaloma is actually malignant swings enormously by organ, from under 5 percent for adrenal and brain findings to roughly 42 percent for breast findings. A finding that is trivial in one location can be dangerous in another. Any sensible approach therefore has to be organ-specific, and it has to treat a spot on the kidney differently from a spot in the breast.

The reasoning underneath the rules#

Strip away the flowcharts and what remains is probability. Each recommendation begins with a pretest probability, the baseline chance that a finding of this type, in a patient like this one, is something serious. Imaging features and patient history then push that estimate up or down until it crosses a threshold for action or reassurance. The algorithms rarely use the word Bayesian, but that is the machinery they run on.

Size thresholds show the logic most plainly. The Fleischner Society sets its minimum follow-up size for solid pulmonary nodules at 6 mm because screening data show the cancer risk below that size sits well under 1 percent. At that low a probability, routine follow-up cannot help enough to justify the scans, radiation, and worry it creates. The cutoff is not arbitrary; it is calibrated to keep the chance of missing something meaningful acceptably small while sparing patients the harm of chasing tiny, almost-always-benign spots.

Specific features act like tie-breakers, each one nudging the estimate. A renal lesion containing visible fat points strongly toward a benign angiomyolipoma. A simple cyst with the density of water and a thin, smooth wall needs no further attention. An adrenal nodule that measures 10 Hounsfield units or less on an unenhanced scan is very likely a harmless lipid-rich adenoma. Every one of these is a reassuring signal strong enough to close the question.

What tips a finding into worth chasing#

Findings earn a workup when their features point the other way. Solid rather than cystic, enhancement after contrast, a thick or irregular wall, a size above the organ-specific cutoff, and, above all, growth compared with an earlier study all raise concern. Growth is the loudest signal of the group, which is why radiologists prize the oldest images they can find. A nodule that has stayed the same for years is reassuring in a way no single snapshot can match, and pulling up prior scans resolves a large share of incidentalomas with no new procedure at all.

Patient context counts as much as the pixels. The same small lung nodule that warrants nothing in a lifelong nonsmoker may warrant a follow-up CT in a heavy smoker, which is exactly why the Fleischner recommendations are stratified by risk. The finding does not change; the person carrying it does, and so does the pretest probability the radiologist starts from.

Turning judgment into shared algorithms#

Left to individual instinct, these decisions would vary from reader to reader. Over the past fifteen years the American College of Radiology (ACR) has worked to standardize them. The foundational document is the 2010 ACR Incidental Findings Committee white paper on incidental findings on abdominal CT, which laid out practical pathways for the kidneys, liver, adrenal glands, and pancreas. Later committees extended the approach to adnexal, vascular, splenic, nodal, gallbladder, and biliary findings, and revised the renal and adrenal guidance as evidence matured.

The series keeps growing. The ACR has added pathways as recently as 2025, including guidance on incidentally discovered pineal cysts, and maintains the whole set as a living resource you can pull up at the workstation. Other groups do the same job for organs the ACR papers do not cover, most prominently the Fleischner Society for lung nodules. Each pathway reads like a decision tree: it asks a short series of questions, is the finding cystic or solid, how large, does it carry reassuring features, does the patient's history raise the stakes, and then routes to one of a few endpoints. Ignore it, describe it and stop, follow it at an interval, or investigate now.

Where the logic runs thin#

The algorithms are only as trustworthy as the evidence behind them, and for some organs that evidence is limited, which is why several pathways offer ranges and clinician discretion instead of firm commands. Beneath that lies the deeper problem of overdiagnosis. A pathway that finds and confirms an indolent lesion has still cost you worry, money, and sometimes an invasive procedure for a condition that would never have surfaced on its own. The guidance is written to shrink that harm, not to erase the uncomfortable fact that looking harder finds more of everything, the useful and the useless together.